Organon, Jersey City, NJ, USA.
Actu-real, Alpharetta, GA, USA.
Ann Pharmacother. 2024 May;58(5):480-493. doi: 10.1177/10600280231190701. Epub 2023 Aug 17.
Bacterial vaginosis (BV) is a highly prevalent vaginal infection.
Primary objectives of this study were to examine treatment patterns among female patients with Medicaid coverage who were diagnosed with incident BV, the frequency of BV-associated complications, and health care resource utilization (HCRU) and associated costs of incident BV and its recurrence. Secondary objectives were to identify predictors of total all-cause health care costs and number of treatment courses.
Female patients aged 12-49 years with an incident vaginitis diagnosis and ≥1 pharmacy claim for a BV medication were selected from the Merative MarketScan Medicaid database (2017-2020). Additional treatment courses were evaluated during a ≥12-month follow-up period, in which new cases of BV-associated complications and HCRU and the associated costs were also measured. Generalized linear models were used to identify baseline predictors of total all-cause health care costs and number of treatment courses.
An incident vaginitis diagnosis and ≥1 BV medication claim were present in 114 313 patients (mean age: 28.4 years; 48.6% black). During the follow-up, 56.6% had 1 treatment course, 24.9% had 2, 10.2% had 3, and 8.3% had ≥4; 43.4% had BV recurrence. Oral metronidazole (88.5%) was the most frequently prescribed medication. Nearly 1 in 5 had a new occurrence of a BV-associated complication; most (76.6%) were sexually transmitted infections (STIs). Total all-cause and BV-related costs averaged $5794 and $300, respectively, per patient; both increased among those with more treatment courses. Older age, pregnancy, comorbidity, any STIs, postprocedural gynecological infection (PGI), and infertility were predictive of higher total all-cause health care costs, while race/ethnicity other than white was predictive of lower costs. Older age, black race, any STIs, pelvic inflammatory disease, and PGI were predictive of >1 treatment courses.
The high recurrence of BV represents an unmet need in women's health care and better treatments are necessary.
细菌性阴道病(BV)是一种高度流行的阴道感染。
本研究的主要目的是检查接受医疗补助保险的女性患者在诊断出细菌性阴道病后的治疗模式、细菌性阴道病相关并发症的发生频率,以及细菌性阴道病及其复发的医疗保健资源利用(HCRU)和相关成本。次要目标是确定总全因医疗保健成本和治疗疗程数的预测因素。
从 Merative MarketScan Medicaid 数据库(2017-2020 年)中选择 12-49 岁、有细菌性阴道病诊断和≥1 种 BV 药物处方的女性患者。在≥12 个月的随访期间评估了其他治疗疗程,在此期间还测量了新的细菌性阴道病相关并发症和 HCRU 及其相关成本。使用广义线性模型确定总全因医疗保健成本和治疗疗程数的基线预测因素。
在 114313 名患者(平均年龄:28.4 岁;48.6%为黑人)中,有细菌性阴道病的诊断和≥1 种 BV 药物的处方。在随访期间,56.6%的患者接受了 1 个疗程治疗,24.9%的患者接受了 2 个疗程治疗,10.2%的患者接受了 3 个疗程治疗,8.3%的患者接受了≥4 个疗程治疗;43.4%的患者出现 BV 复发。最常开的药物是口服甲硝唑(88.5%)。近 1/5 的患者出现新的细菌性阴道病相关并发症;大多数(76.6%)为性传播感染(STI)。每位患者的总全因和与 BV 相关的费用平均分别为 5794 美元和 300 美元,随着治疗疗程的增加而增加。年龄较大、妊娠、合并症、任何 STI、妇科手术后感染(PGI)和不孕是总全因医疗保健费用较高的预测因素,而种族/民族(非白人)是费用较低的预测因素。年龄较大、黑人种族、任何 STI、盆腔炎和 PGI 是接受>1 个疗程治疗的预测因素。
BV 的高复发率代表了女性健康护理中的未满足需求,需要更好的治疗方法。